Discovery and Characterization of ACT-335827, an Orally Available, Brain Penetrant Orexin Receptor Type1 Selective Antagonist

被引：74
|
作者：
Steiner, Michel A. [1 ]
Gatfield, John [1 ]
Brisbare-Roch, Catherine [1 ]
Dietrich, Hendrik [1 ]
Treiber, Alexander [1 ]
Jenck, Francois [1 ]
Boss, Christoph [1 ]
机构：
[1] Actel Pharmaceut Ltd, CH-4123 Allschwil, Switzerland
来源：
CHEMMEDCHEM | 2013年 / 8卷 / 06期
关键词：
anxiety; neurotransmitters; orexin receptor antagonists; peptides; sleep; SLEEP; PROMOTION; SYSTEM;
D O I：
10.1002/cmdc.201300003
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Stress relief: Orexin neuropeptides regulate arousal and stress processing through orexin receptor type1 (OXR-1) and 2 (OXR-2) signaling. A selective OXR-1 antagonist, represented by a phenylglycine-amide substituted tetrahydropapaverine derivative (ACT-335827), is described that is orally available, penetrates the brain, and decreases fear, compulsive behaviors and autonomic stress reactions in rats. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
引用
收藏
页码：898 / 903
页数：6
相关论文
共 50 条
  • [21] First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist
    Kaufmann, Priska
    Ort, Marion
    Golor, Georg
    Kornberger, Rudiger
    Dingemanse, Jasper
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (07) : 1377 - 1386
  • [22] Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders
    Di Fabio, Romano
    Pellacani, Annalisa
    Faedo, Stefania
    Roth, Adelheid
    Piccoli, Laura
    Gerrard, Philip
    Porter, Rod A.
    Johnson, Christopher N.
    Thewlis, Kevin
    Donati, Daniele
    Stasi, Luigi
    Spada, Simone
    Stemp, Geoffrey
    Nash, David
    Branch, Clive
    Kindon, Leanda
    Massagrande, Mario
    Poffe, Alessandro
    Braggio, Simone
    Chiarparin, Elisabetta
    Marchioro, Carla
    Ratti, Emiliangelo
    Corsi, Mauro
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (18) : 5562 - 5567
  • [23] Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313
    Kaufmann, Priska
    Ort, Marion
    Golor, Georg
    Kornberger, Ruediger
    Dingemanse, Jasper
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2021, 108
  • [24] TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy
    Ishikawa, Takashi
    Hara, Hiroe
    Kawano, Ayumi
    Tohyama, Kimio
    Kajita, Yuichi
    Miyanohana, Yuhei
    Koike, Tatsuki
    Kimura, Haruhide
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385 (03): : 193 - 204
  • [25] Discovery of a novel, orally available orexin 2 receptor-selective agonist, TAK-988, as a potential therapeutic drug for narcolepsy.
    Kimura, H.
    Ishikawa, T.
    Kajita, Y.
    Miyanohana, Y.
    Koike, T.
    Suzuki, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 409 - 409
  • [26] Discovery and preclinical characterization of PQR626: A potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of tuberous sclerosis complex
    Borsari, Chiara
    Keles, Erhan
    Rageot, Denise
    Melone, Anna
    Bohnacker, Thomas
    Batchelor, Lucinda Kate
    De Pascale, Martina
    Hebeisen, Paul
    Hillmann, Petra
    Fabbro, Doriano
    Wymann, Matthias
    CANCER RESEARCH, 2020, 80 (16)
  • [27] DISCOVERY OF A NOVEL ORALLY AVAILABLE SELECTIVE OREXIN 2 RECEPTOR AGONIST, E2086, AS A THERAPEUTIC DRUG FOR NARCOLEPSY AND OTHER HYPERSOMNIA DISORDERS
    Hatanaka, K.
    Suzuki, H.
    Michikawa, F.
    Koba, R.
    Osada, Y.
    Beuckmann, C.
    Landry, I.
    Moline, M.
    Ishikawa, Y.
    SLEEP MEDICINE, 2022, 100 : S103 - S103
  • [28] Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
    Glen, Angela
    Buerli, Roland W.
    Livermore, David
    Buffham, William
    Merison, Stephanie
    Rowland, Anna E.
    Newman, Robert
    Fieldhouse, Charlotte
    Miller, David J.
    Dawson, Lee A.
    Matthews, Kim
    Carlton, Mark B.
    Brice, Nicola L.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 100
  • [29] EVALUATION OF A NOVEL, ORALLY AVAILABLE OREXIN 2 RECEPTOR AGONIST, ON WAKEFULNESS AND CATAPLEXY IN A MOUSE MODEL OF TYPE 1 NARCOLEPSY
    Brooks, J.
    Sun, Y.
    Kilduff, T.
    Tan, L.
    Raymer, B.
    SLEEP MEDICINE, 2024, 115 : 216 - 216
  • [30] Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases
    Lescop, Cyrille
    Birker, Magdalena
    Brotschi, Christine
    Burki, Cedric
    Morrison, Keith
    Froidevaux, Sylvie
    Delahaye, Stephane
    Nayler, Oliver
    Bolli, Martin H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (04) : 2397 - 2424
12345